MGMT and glioblastoma: Although the median survival time of patients with GBM receiving the Stupp regimen is only 14.6 months, it is noteworthy that patients with low O6‐methylguanine DNA‐methyltransferase (MGMT) expression benefit more from TMZ chemotherapy than patients with high MGMT expression.2 According to a recent study, the median OS of a low MGMT group of patients with GBM receiving the Stupp regimen was 21.8 months, while that of a high MGMT group was only 13.1 months.3